Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.

Autor: Fakih M; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Raghav KPS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang DZ; Virginia Oncology Associates, Newport News, VA, USA., Larson T; Minnesota Oncology/The US Oncology Network, Minneapolis, MN, USA., Cohn AL; Rocky Mountain Cancer Center, Denver, CO, USA., Huyck TK; Nebraska Cancer Specialists, Omaha, NE, USA., Cosgrove D; Division of Medical Oncology, Vancouver Cancer Center, Compass Oncology, Vancouver, WA, USA., Fiorillo JA; Willamette Valley Cancer Institute, Eugene, OR, USA., Tam R; Bristol Myers Squibb, Lawrenceville, NJ, USA., D'Adamo D; Bristol Myers Squibb, Lawrenceville, NJ, USA., Sharma N; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA., Brennan BJ; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA., Wang YA; Bayer HealthCare Pharmaceuticals, Cambridge, MA, USA., Coppieters S; Bayer AG, Diegem, Belgium., Zebger-Gong H; Bayer AG, Berlin, Germany., Weispfenning A; Bayer AG, Berlin, Germany., Seidel H; Bayer AG, Berlin, Germany., Ploeger BA; Bayer AG, Berlin, Germany., Mueller U; ClinStat GmbH, Cologne, Germany., Oliveira CSV; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA., Paulson AS; Texas Oncology/The US Oncology Network, Dallas, TX, USA.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2023 Apr 06; Vol. 58, pp. 101917. Date of Electronic Publication: 2023 Apr 06 (Print Publication: 2023).